Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$6.42
-0.16-2.43%
At close: -
$6.43
0.010000.16%
After Hours: May 23, 6:22 PM EDT
Comments
Loading...
Abeona Therapeutics Analyst Ratings and Price Targets | NASDAQ:ABEO | Benzinga
Abeona Therapeutics Inc has a consensus price target of $16.43 based on the ratings of 7 analysts. The high is $20 issued by Stifel on May 16, 2025. The low is $6 issued by SVB Leerink on November 14, 2022. The 3 most-recent analyst ratings were released by Stifel, HC Wainwright & Co., and HC Wainwright & Co. on May 16, 2025, April 30, 2025, and March 24, 2025, respectively. With an average price target of $18.33 between Stifel, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 185.12% upside for Abeona Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Stifel
HC Wainwright & Co.
HC Wainwright & Co.
Oppenheimer
Cantor Fitzgerald
1calculated from analyst ratings
Analyst Ratings for Abeona Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/16/2025 | Buy Now | 211.04% | Stifel | Dae Gon Ha48% | $21 → $20 | Maintains | Buy | Get Alert |
| 04/30/2025 | Buy Now | 211.04% | HC Wainwright & Co. | Raghuram Selvaraju43% | $15 → $20 | Maintains | Buy | Get Alert |
| 03/24/2025 | Buy Now | 133.28% | HC Wainwright & Co. | Mitchell Kapoor44% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 03/05/2025 | Buy Now | 148.83% | Oppenheimer | Francois Brisebois40% | → $16 | Initiates | → Outperform | Get Alert |
| 02/19/2025 | Buy Now | 133.28% | HC Wainwright & Co. | Mitchell Kapoor44% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 11/25/2024 | Buy Now | 133.28% | HC Wainwright & Co. | Raghuram Selvaraju43% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 10/31/2024 | Buy Now | 133.28% | HC Wainwright & Co. | Raghuram Selvaraju43% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 10/29/2024 | Buy Now | 179.94% | Cantor Fitzgerald | Kristen Kluska71% | $18 → $18 | Reiterates | Overweight → Overweight | Get Alert |
| 09/20/2024 | Buy Now | 179.94% | Cantor Fitzgerald | Kristen Kluska71% | $18 → $18 | Reiterates | Overweight → Overweight | Get Alert |
| 08/14/2024 | Buy Now | 133.28% | HC Wainwright & Co. | Raghuram Selvaraju43% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 07/12/2024 | Buy Now | 133.28% | HC Wainwright & Co. | Raghuram Selvaraju43% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 07/03/2024 | Buy Now | 133.28% | HC Wainwright & Co. | Raghuram Selvaraju43% | → $15 | Initiates | → Buy | Get Alert |
| 05/30/2024 | Buy Now | 226.59% | Stifel | Dae Gon Ha48% | → $21 | Initiates | → Buy | Get Alert |
| 05/16/2024 | Buy Now | 226.59% | Cantor Fitzgerald | Kristen Kluska71% | $28 → $21 | Maintains | Overweight | Get Alert |
| 04/23/2024 | Buy Now | 459.88% | Cantor Fitzgerald | Kristen Kluska71% | $36 → $36 | Reiterates | Overweight → Overweight | Get Alert |
| 08/24/2023 | Buy Now | 490.98% | Cantor Fitzgerald | Kristen Kluska71% | → $38 | Reiterates | Overweight → Overweight | Get Alert |
| 07/13/2023 | Buy Now | 490.98% | Cantor Fitzgerald | Kristen Kluska71% | → $38 | Reiterates | Overweight → Overweight | Get Alert |
| 05/24/2023 | Buy Now | 211.04% | Alliance Global Partners | James Molloy30% | → $20 | Reiterates | → Buy | Get Alert |
| 11/14/2022 | Buy Now | -6.69% | SVB Leerink | Mani Foroohar47% | $5 → $6 | Maintains | Market Perform | Get Alert |
| 11/08/2022 | Buy Now | 522.08% | Cantor Fitzgerald | Kristen Kluska71% | $22 → $40 | Maintains | Overweight | Get Alert |
| 08/11/2022 | Buy Now | -22.24% | SVB Leerink | Mani Foroohar47% | $1 → $5 | Maintains | Market Perform | Get Alert |
FAQ
What is the target price for Abeona Therapeutics (ABEO) stock?
The latest price target for Abeona Therapeutics (NASDAQ:ABEO) was reported by Stifel on May 16, 2025. The analyst firm set a price target for $20.00 expecting ABEO to rise to within 12 months (a possible 211.04% upside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Abeona Therapeutics (ABEO)?
The latest analyst rating for Abeona Therapeutics (NASDAQ:ABEO) was provided by Stifel, and Abeona Therapeutics maintained their buy rating.
When was the last upgrade for Abeona Therapeutics (ABEO)?
There is no last upgrade for Abeona Therapeutics
When was the last downgrade for Abeona Therapeutics (ABEO)?
There is no last downgrade for Abeona Therapeutics.
When is the next analyst rating going to be posted or updated for Abeona Therapeutics (ABEO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Abeona Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Abeona Therapeutics was filed on May 16, 2025 so you should expect the next rating to be made available sometime around May 16, 2026.
Is the Analyst Rating Abeona Therapeutics (ABEO) correct?
While ratings are subjective and will change, the latest Abeona Therapeutics (ABEO) rating was a maintained with a price target of $21.00 to $20.00. The current price Abeona Therapeutics (ABEO) is trading at is $6.43, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
